$ASND Reports 144% Revenue Surge but Misses EPS Estimates
Ascendis Pharma posted 144.3% revenue growth in its most recent quarter but missed EPS estimates by 2.2%. ACCE score sits at 60/100. Full breakdown inside.
$ASND (Ascendis Pharma) reported earnings for its most recent quarter (reported August 13, 2026), and the headline number that stands out is revenue growth of +144.3% year over year. That is a substantial acceleration for a healthcare company of this size.
On the earnings side, EPS came in at -$0.93, exactly flat versus -$0.93 in the same period a year earlier. The loss held steady rather than narrowing or widening, which means the company is not yet converting its revenue surge into bottom-line improvement. The result still missed analyst estimates by 2.2%.
We do not have guidance commentary from management to add context to these figures.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
What it means
The ACCE score for $ASND sits at 60/100, a middling read that reflects some real tension in the underlying data. The score breakdown tells the story clearly: Quality scores 74 and Momentum scores 77, both solid. Growth scores 64, which aligns with the triple-digit revenue expansion. Value, however, scores just 26 out of 100.
That low Value score is worth paying attention to. The stock trades at a trailing P/E of 29.2 and a forward P/E of 15.9, suggesting the market expects profitability to improve materially. The 6-model fair value estimate of $151.02 sits 38.7% below the current price of $246.33, which is a wide gap. That does not mean the stock falls to fair value, but it does mean the current price prices in a lot of continued execution.
Net margin of +57.3% and ROE of +33.3% are genuinely strong quality metrics. FCF yield of just +0.3% is thin, and the data flags earnings quality as concerning, which warrants attention given the disconnect between reported profitability and cash generation.
The analyst consensus target of $308.53 sits above the current price, implying roughly 25% upside from here in the analyst community's view. That contrasts sharply with the 6-model fair value signal.
The 1-year return of +28.9% shows the stock has rewarded holders over the past year, and the Momentum score of 77 reflects that recent price strength.
For current price and additional data, see the live page at acceinvestments.com/stocks/ASND.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
